NEW YORK, May 30, 2026, 15:03 EDT
- Intuitive Surgical finished Friday at $424.64. The stock dropped about 3.1% over the holiday-shortened week.
- Nasdaq stays closed Saturday. Trading starts again Monday, with U.S. indexes ending the week on a high note.
- Investors look at a May 28 leadership change in commercial, along with strong first-quarter procedure growth, and tariff risk.
Intuitive Surgical shares slipped over a choppy, holiday-shortened week, while the major indexes kept rising to new records. That has put another spotlight on the robotic-surgery maker’s ability to convert a run of solid procedure growth into share gains.
Intuitive Surgical shares finished Friday at $424.64 on Nasdaq, a gain of 0.24% for the session. The stock touched a low of $419.83 during the day. Shares are still down roughly 3.1% from the May 22 close at $438.10, according to the company’s LSEG historical data.
Market timing is in focus since the exchange is shut on Saturday. Nasdaq trades Monday to Friday from 9:30 a.m. to 4:00 p.m. Eastern, and U.S. markets didn’t open on May 25 because of Memorial Day. That left investors with just four sessions this week to adjust positions.
The wider market’s move didn’t help Intuitive. The S&P 500 climbed 1.4% for the week, and the Nasdaq Composite was up 2.4%. The Associated Press said that’s nine weekly gains in a row for the S&P 500.
Intuitive Surgical is making a top commercial leadership change. In a May 28 SEC filing, the company said Henry Charlton will go from chief commercial and marketing officer to SVP of global business operations starting July 1. Taylor Patton, now global SVP for endoluminal, will step into the commercial chief job.
Intuitive called it an internal transition at a key point in its growth. CEO Dave Rosa said Patton’s long tenure at Intuitive made him “uniquely positioned” to take over. Patton pointed to customers’ focus on “meaningful and differentiated outcomes” and on bringing down the total cost to treat. Intuitive Surgical
The focus this week isn’t really a specific date for Intuitive. What’s at stake is whether the company can show it’s executing. In this industry, “procedure growth” just means how many surgeries are done with its machines. It’s important since more procedures typically drive higher sales from tools, add-ons, and service contracts.
Q1 numbers are still the focus. Intuitive reported April 21 that revenue climbed 23% to $2.77 billion. da Vinci procedures jumped around 16%, Ion procedures went up roughly 39%. The company installed 431 da Vinci systems in the quarter, with 232 of those da Vinci 5 models.
Market caution lingers despite the growth. On the earnings call, management noted U.S. bariatric procedures fell about 10% as demand dropped with the rise of GLP-1 weight-loss drugs. China is still tough due to fewer tenders, more competition and pricing pressure.
But the risk is obvious. Intuitive projects non-GAAP gross margin at 67.5% to 68.5% of revenue in 2026, after an expected tariff impact of about 1.0%. This margin measure strips out certain accounting costs. The company also said more tariffs could hit results in a big way.
Competitive moves stood out Friday with Intuitive climbing as some other medtech stocks moved lower. Medtronic lost 2.33%, and Stryker finished 0.83% lower in the session, according to MarketWatch data. Investors have been picking among device names lately.
Macro risks could still flip the script for stocks. Reuters said investors are waiting on the June 5 U.S. payrolls print, where a poll tips 85,000 new jobs and 4.3% jobless. Liz Ann Sonders, Schwab Center for Financial Research, told Reuters that a strong jobs number and higher inflation would reset Fed policy views.
